Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lenalidomide in HIV-associated Kaposi Disease
NCT01282047Phase 2Terminated
- Sponsor
- ANRS
- Start
- Oct 2011
- Primary completion
- Feb 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of lenalidomide in Kaposi sarcoma (KS), sponsored by ANRS. Primary endpoint: Clinical benefit of treatment with Lenalidomide at 24 weeks. Started Oct 2011; status: terminated.
02
Drugs
lenalidomide
03
Conditions
Kaposi sarcoma (KS)
Beyond the preview
Go deeper on NCT01282047.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01282047.